Valion Bio
VBIO
1 hedge funds and large institutions have $43.4K invested in Valion Bio in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
45% more capital invested
Capital invested by funds: $30K → $43.4K (+$13.4K)
0.48% more ownership
Funds ownership: 0.22% → 0.7% (+0.48%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$56.1K |
Top Sellers
VBIO Hedge Fund Activity: Q4 2022 in Review
1 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q4 2022, worth a combined $43.4K — up 45% from $30K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new VBIO positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $56.1K.
- 1 institutional investor held Valion Bio (VBIO) as of Q4 2022, up from 0 in Q3 2022.
- Funds reported $43.4K of Valion Bio stock for Q4 2022, up 45% quarter-over-quarter.
- 1 fund opened new Valion Bio positions in Q4 2022 and 0 closed out, a net change of +1 holder.
- The largest Valion Bio buyer in Q4 2022 was Renaissance Technologies, an estimated $56.1K added.
Based on aggregated 13F filings for Q4 2022.